Company / Cash & Equivalents
BioAge Labs, Inc. Cash & Equivalents History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$188.9M
FY2025
5-year range
$21.6M / $354.3M
FY2023-FY2025
Trend
-46.7%
vs FY2024
Sector context
#93 of 207
Health Care
What the data says
At $189M, BioAge Labs, Inc.'s cash & equivalents ranks #93 of 207 in the Health Care sector. Improved from $22M to $189M over the past 2 years.
Based on SEC 10-K filings.
$189M in FY2025.
Improved from $22M to $189M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#93 of 207 in Health CareTop 45% of 207This company $188.9M Sector average $669.5M
▼
-71.8% below sector average
Key checks
Key Insights
- In FY2025, cash & equivalents decreased 46.7% year-over-year.
- Ranks #93 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.75 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $188.9M | -46.7% |
| FY2024 | $354.3M | +1537.2% |
| FY2023 | $21.6M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026